ArticleCancer letters2018
Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer.
Article in Cancer letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 45 citations in OpenAlex.
- Targeted extracellular degradation of LRP8 promotes ferroptosis in cancer cells.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Architecting NIR-II metal supramolecular dyes-illuminating the path to precision medicine.Chemical science · 2026Review
- LRP8 Promotes colorectal cancer progression by suppressing ferroptosis through the SLC3A2/GPX4 signalling axis.European journal of medical research · 2026Article
- High glucose promotes cisplatin chemoresistance in MDA-MB-231 breast cancer derived cells through changes in gene expression and multiple signaling pathways.Biomedical reports · 2025Article
- LRP8 Regulates Lipid Metabolism to Stimulate Malignant Progression and Cisplatin Resistance in Bladder Cancer.The Kaohsiung journal of medical sciences · 2025Article
- Reelin-LRP8 signaling mediates brain dissemination of breast cancer cells via abluminal migration.EMBO molecular medicine · 2025Article
- Drug Resistance Analysis of Pancreatic Cancer Based on Universally Differentially Expressed Genes.International journal of molecular sciences · 2025Article
- LRP8-dependent cholesterol metabolism modulates mTORC1 signaling and apoptotic pathways in multiple myeloma.Cell death & disease · 2025Article
- Enhanced LRP8 expression induced by Helicobacter pylori drives gastric cancer progression by facilitating β-Catenin nuclear translocation.Journal of advanced research · 2025Article
- Pharmacological activity of OST-01, a natural product from baccharis coridifolia, on breast cancer cells.Journal of hematology & oncology · 2025Article
- Identification and validation of a novel nine-gene prognostic signature of stem cell characteristic in hepatocellular carcinoma.Journal of applied genetics · 2025Article
- MiR-378a-5p exerts a radiosensitizing effect on CRC through LRP8/β-catenin axis.Cancer biology & therapy · 2024Article
- The multifaceted therapeutical role of low-density lipoprotein receptor family in high-grade glioma.Molecular oncology · 2024Review
- Phosphorus Metabolism-Related Genes Serve as Novel Biomarkers for Predicting Prognosis in Bladder Cancer: A Bioinformatics Analysis.Iranian journal of public health · 2024Review
- PCSK9 genetic variants and risk of vascular and non-vascular diseases in Chinese and UK populations.European journal of preventive cardiology · 2024Article
- A Novel Methylation-based Model for Prognostic Prediction in Lung Adenocarcinoma.Current genomics · 2024Article
- USP22 supports the aggressive behavior of basal-like breast cancer by stimulating cellular respiration.Cell communication and signaling : CCS · 2024Article
- The Analysis of ceRNA Networks and Tumor Microenvironment in Endometrial Cancer.Journal of Cancer · 2024Article
- The therapeutic effect of traditional Chinese medicine on breast cancer through modulation of the Wnt/β-catenin signaling pathway.Frontiers in pharmacology · 2024Review
- Review
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Triple-negative breast cancer (TNBC) is the most difficult subtype of breast cancer to treat due to a paucity of effective targeted therapies. Many studies have reported that breast cancer stem cells (BCSCs) are enriched in TNBC and are responsible for chemoresistance and metastasis. In this study, we identify LRP8 as a novel positive regulator of BCSCs in TNBC. LRP8 is highly expressed in TNBC compared to other breast cancer subtypes and its genomic locus is amplified in 24% of TNBC tumors. Knockdown of LRP8 in TNBC cell lines inhibits Wnt/β-catenin signaling, decreases BCSCs, and suppresses tumorigenic potential in xenograft models. LRP8 knockdown also induces a more differentiated, luminal-epithelial phenotype and thus sensitizes the TNBC cells to chemotherapy. Together, our study highlights LRP8 as a novel therapeutic target for TNBC as inhibition of LRP8 can attenuate Wnt/β-catenin signaling to suppress BCSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.